18 Several cell-based studies employed CMPD1 as a MK2 inhibitor at various concentrations (0.3–50 μM30–34); but only one study demonstrated that CMPD1 at 10 μM inhibited TNF-α induced activation of the MK2 pathway.35 We present here that in U87 glioblastoma cells, CMPD1 at concentrations up to 10 μM did not inhibit the activation of MK2 and Hsp27. The gene discussed is SOX9; the disease is glioblastoma.